Effekten af ivabradin på angina pectoris og iskæmi var bevaret hos diabetespatienter (n = 457) med samme sikkerhedsprofil som for hele populationen.
The antianginal and anti-ischaemic efficacy of ivabradine was preserved in diabetic patients (n = 457) with a similar safety profile as compared to the overall population.